PARP Inhibitors in Ovarian Cancer: A Review
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · The Ohio State University · +5 more institutions
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, with a focus on the use of PARPis as maintenance therapy in the United States (US). Olaparib was the first PARPi to be approved as first-line maintenance monotherapy in the US, with maintenance niraparib subsequently approved in the first-line setting. Data also support the efficacy of rucaparib as first-line maintenance monotherapy. PARPi maintenance combination therapy (olaparib plus bevacizumab) also provides…
Citation impact
- FWCI
- 38.47
- Percentile
- 100%
- References
- 118
Authors
5- DMDavid M. O’MalleyCorresponding
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
- TCThomas C. Krivak
Allegheny Health Network
- NKNashwa Kabil
AstraZeneca (United States)
- JMJiefen Munley
AstraZeneca (United States), National Patient Safety Foundation
- KNKathleen N. Moore
Oklahoma State University Oklahoma City, University of Oklahoma
Topics & keywords
- Olaparib
- Medicine
- PARP inhibitor
- Oncology
- Maintenance therapy
- Ovarian cancer
- Tolerability
- Internal medicine
- Good health and well-being